Astellas Pharma on LinkedIn: #breakingnews #gastriccancer (original) (raw)
Astellas Pharma’s Post
#BreakingNews: The U.S. FDA has approved our claudin 18.2-directed antibody for the treatment of adults with advanced gastric or GEJ cancer. https://lnkd.in/gUaryS7BWith this approval, adults with locally advanced unresectable or metastatic HER2-negative #GastricCancer or GEJ adenocarcinoma and claudin (CLDN) 18.2-positive tumors now have a targeted treatment option. We’re proud to take a step forward in the fight against this devastating disease.
``